Revian, based in Morrisville, N.C., offers an at-home, wireless cap that uses patented dual-wavelength red light to stimulate nitric oxide production, inhibit DHT, improve scalp circulation, and reduce inflammation—three biological drivers of hair loss. The device is FDA-cleared for androgenetic alopecia in both male and female patients and has demonstrated the best clinical trial performance among hair-rejuvenation therapies, according to the company. An accompanying mobile app lets physicians monitor patient compliance in real time, differentiating Revian’s solution in a crowded market. Backed by strong clinical data, Revian follows a physician-led distribution model that is reportedly scaling quickly. The firm plans to leverage new capital to ramp commercial operations, expand its product line, and enter international markets. Revian operates as an affiliate of KNOW Bio, LLC and focuses on non-pharmacologic, light-based therapies for hair and skin. No revenue or user figures were disclosed in the announcement.

Total raised

$13M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2025